A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Biocomposites Ltd
Study ID
NCT06283979
Phase
PHASE2
Status
Recruiting

Conditions

  • Osteomyelitis
  • Pressure Ulcer, Stage IV

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • STIMULAN VG — COMBINATION_PRODUCT
    Insertion of STIMULAN VG into the ulcer cavity prior to flap/primary closure.
  • Standard of Care — PROCEDURE
    Standard of Care. Ulcer bursectomy, debridement and flap/primary closure. Peri-operative antibiotics.

Study Details

The purpose of this trial is to assess the safety, tolerability and between-group effect size of STIMULAN VG (with debridement) and a course of systemic antibiotics to standard of care (debridement and systemic antibiotics only) for the treatment of osteomyelitis associated stage IV pressure ulcers.

Key Dates

Start date
Jun 15, 2025
Status verified
Oct 2025
Primary completion
Dec 1, 2026
Completion
Dec 1, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Interventional STIMULAN VG
    Ulcer bursectomy and debridement and STIMULAN VG insertion into the ulcer cavity. Flap/primary closure. Peri-operative antibiotics.
  • Active Comparator: Standard of Care (SoC)
    Ulcer bursectomy, debridement and flap/primary closure. Peri-operative antibiotics.

Primary Outcome Measure

Individual patient success and findings at the 8 week follow-up visit [ Time Frame: 8 week ]

Central Contacts

Locations (9)

FacilityCityStateZIPSite coordinators
Advanced Foot Care, LLCPhoenixArizona85032
Krishna Sai Penumarthi
(480) 863-6044
Rajashekhar Ittedi
(480) 863-6044
Jaminelli Banks, DPM (PRINCIPAL_INVESTIGATOR)
Northwestern University Feinberg School of MedicineChicagoIllinois60611
Brigid Coles
312-503-3209
Tarifa Adam
312-503-3209
Robert Galiano, MD (PRINCIPAL_INVESTIGATOR)
Henry Ford HospitalDetroitMichigan48202
Sarah Meehan
Aamir Siddiqui, MD (PRINCIPAL_INVESTIGATOR)
University of Mississippi Medical CenterJacksonMississippi39216
Venkata Seerapu
Laxmi Dhungel
Ian Hoppe, MD (PRINCIPAL_INVESTIGATOR)
Missouri Orthopaedic InstituteColumbiaMissouri65201
Andrew Monhollen
Brett Crist, MD (PRINCIPAL_INVESTIGATOR)
University of Nebraska Medical CenterOmahaNebraska68198
Katie Ostlund
Gabriel Gauthier
James Willcockson, MD (PRINCIPAL_INVESTIGATOR)
Rutgers New Jersey Medical SchoolNewarkNew Jersey07103
Saharsh Patel
Mehreen Bhatti
Alex Wong, MD, FACS (PRINCIPAL_INVESTIGATOR)
NYU Langone Hospital - Long Island Clinical Research CenterMineolaNew York11501
Anita Farha
516 663 9582
Monica Benitez
516 663 9582
Scott Gorenstein, MD (PRINCIPAL_INVESTIGATOR)
University of Pittsburgh, McGowan Institute for Regenerative MedicinePittsburghPennsylvania15219
Urmila Gnyawali
412-624-5500
Scot King
412-624-5500
Sashwati Roy, PhD, MS (PRINCIPAL_INVESTIGATOR)

Find similar trials in Phoenix, AZ

Related Studies